415 Capital Management
415 Capital is a Munich based specialist medtech venture capital firm founded in 2019 by David Thompson and Frank and Frederik Groenewegen. It backs early and clinical-stage medical device and digital-health companies focused on cardiovascular and neurovascular disease across Europe, the United States and Israel. The founding team has privately funded more than 45 medtech startups with over 25 realized exits, and the firm now manages Fund I from 2020 and Fund II launched in 2024.
Key facts
Recent exits
No exits recorded yet.
Coverage notes
2 funds tracked, 9 portfolio companies (9 active · 0 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund 415 Capital Management has raised, with its portfolio companies. Hand-checked from public filings.
415 Capital Fund IIVC2024 · 2yr2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| MedTech |  Switzerland | 2024 | |
| MedTech |  US | 2025 |
Switzerland· Entry 2024US· Entry 2025415 Capital Fund IVCHarvesting2020 · 6yr7 active
Unrealized
7 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| MedTech | Israel | 2021 | |
| MedTech | Switzerland | 2022 | |
| MedTech | Switzerland | 2021 | |
| MedTech | US | 2023 | |
| MedTech | US | 2020 | |
| MedTech | US | 2020 | |
| MedTech |  Germany | 2022 |
Switzerland· Entry 2022Switzerland· Entry 2021US· Entry 2023US· Entry 2020US· Entry 2020Germany· Entry 2022Saved GPs appear in your watchlist, one click from your workspace.
About 415 Capital Management
415 Capital is a specialist medtech venture capital firm with more than €300 million of assets under management across two funds as of December 2024 (Fund I approximately €100 million 2020, Fund II €150 million target with first close announced November 2024), headquartered in Munich (Oberhaching). The firm was founded with Fund I launching in 2018-2020 and a team carrying 25 plus years of medtech investing heritage, operating as an independent partner-owned medtech VC with LPs including the EIF, KfW Capital, Wachstumsfonds Deutschland and family offices.
Investment thesis
415 Capital deploys capital through two funds, targeting clinical-stage medtech venture capital that backs breakthrough and life-saving device companies with capital, clinical expertise and market access. Sector focus spans cardiovascular, neurovascular, neuromodulation, medical robotics and patient monitoring and medical imaging plus AI. Geographic deployment spans Europe, the United States and Israel. The platform combines a cardiovascular and neurovascular medtech specialism with an in-house physician network feeding proprietary clinical insight into deal selection, having funded 50 plus medtech companies over the team's history.
Recent activity
Recent realised exits across the team's history span 25 plus medtech and medical device trade sales and IPOs, with no new 2024-2026 exit individually verified. Recent acquisitions include two clinical-stage cardiovascular companies funded from Fund II (2024-2025), with active portfolio additions including Endovascular Engineering and Laza Medical. The platform continues active deployment of Fund II across the clinical-stage medtech mandate. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€300000.0B
Germany·€20.0B
Germany·€3.0B
Germany·€2.8B
Germany·€2.5B
Germany·€2.3B
Germany·€1.9B
Germany·€1.8B
Germany·€1.8B
Germany·€1.5B
Germany·€1.5B
Germany·€1.4BGet the full picture on 415 Capital Management.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in